FDA approves darolutamide for metastatic hormone-sensitive prostate cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

On August 5, 2022, FDA approved Nubeqa (darolutamide) tablets in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer (mHSPC).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login